
AC Immune (ACIU) Stock Forecast & Price Target
AC Immune (ACIU) Analyst Ratings
Bulls say
AC Immune SA is positioned favorably within the clinical-stage biopharmaceutical sector focused on neurodegenerative diseases, leveraging proprietary technology platforms to advance a promising pipeline. The substantial 20-fold increase in antibodies associated with its PD active immunotherapy ACI-7104.056, along with a strategic approach to drug delivery that mitigates potential adverse effects, underscores the potential efficacy and safety of its treatments. Furthermore, the potential for increased interest in the NLRP3 program, particularly contingent on positive results from the upcoming EVOKE trial in Alzheimer's Disease patients, enhances the company's growth prospects and investor attractiveness.
Bears say
AC Immune SA recorded a net operating loss of CHF 16.2 million, highlighting ongoing financial challenges. The company is exposed to significant risks inherent in the biopharmaceutical industry, including potential adverse outcomes from clinical trials, regulatory uncertainties, and the pressures of navigating complex and price-sensitive commercial markets. These factors contribute to a persistently negative outlook on the company's financial stability and growth prospects.
This aggregate rating is based on analysts' research of AC Immune and is not a guaranteed prediction by Public.com or investment advice.
AC Immune (ACIU) Analyst Forecast & Price Prediction
Start investing in AC Immune (ACIU)
Order type
Buy in
Order amount
Est. shares
0 shares